drugset

drugset / Trial / NCT02256189

Sitagliptin and Glucagon Counterregulation

NCT02256189 ↗

Phase 4 Completed 28 enrolled Lund University Merck Sharp & Dohme LLC · collab

RandomizedCrossoverDouble-blindBasic science

Summary

To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM

Timeline

Start: 2015-04
Primary completion: 2017-06
Completion: 2017-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sitagliptin	Small molecule	100 mg	—

Indications